Company Profile

Anant Raj has informed that the Finance and Investment Committee has, at its meeting held on January 12, 2024, inter-alia, considered and passed the following resolutions: (a) Authorising the opening of the Issue today i.e. January 12, 2024, (b) approving and adopting of the preliminary placement document dated January 12, 2024 and the application form in connection with the Issue; and (c) approving the floor price for the Issue, being Rs 310.78 per Equity Share ('Floor Price'), based on the pricing formula as prescribed under SEBI ICDR Regulations.

The above information is a part of company’s filings submitted to BSE.

Anant Raj is currently trading at Rs. 249.85, up by 1.10 points or 0.44% from its previous closing of Rs. 248.75 on the BSE.

The scrip opened at Rs. 250.65 and has touched a high and low of Rs. 251.60 and Rs. 247.70 respectively. So far 52530 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 252.95 on 08-Nov-2023 and a 52 week low of Rs. 88.05 on 26-Dec-2022.

Last one week high and low of the scrip stood at Rs. 252.95 and Rs. 241.20 respectively. The current market cap of the company is Rs. 8133.20 crore.

The promoters holding in the company stood at 63.31%, while Institutions and Non-Institutions held 11.17% and 25.53% respectively.

Anant Raj has received approval for the issuance of equity shares or other convertible securities by way of Qualified Institutions Placement (QIP), for an aggregate consideration not exceeding Rs 500 crore only in accordance with the applicable laws including the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, each as amended, subject to receipt of all necessary approvals, if and to the extent required. The Board of Directors of the company at their meeting held on November 11, 2023 have inter-alia considered and approved the same. 

Anant Raj has become synonymous with the highest quality, excellence and innovation in the field of construction and real estate development. As one of India's leading infrastructure development enterprise armed with an extensive land bank, the group is in the process of revolutionizing corporate spaces with the development of Special Economic Zones and IT Parks.

ICRA has acquired 60% shareholding in D2K Technologies India (D2K), for an aggregate consideration of Rs 15.4 crore on November 10, 2023, and consequently D2K has become a step-down subsidiary of ICRA. D2K is engaged in the business of providing banking and finance solutions, software services to banks and other financial institutions, corporate etc. 

Dr. Reddy's Laboratories has acquired 26% of the paid up equity share capital of O2 Renewable Energy IX (SPV) in the first tranche, in accordance with terms and conditions of the Security Subscription and Shareholders’ Agreement (SSHA). The object of acquisition is to access renewable power through solar and wind power plants through (Inter-State Transmission System) ISTS under captive structure. 

As a Renewable Energy Implementing Agency (REIA), SJVN has successfully concluded its first ever e-reverse auction (e-RA) for selection of RE power developers for supply of 1,500 MW power projects with energy storage system in India.

Alok Industries has entered into facility agreements with Axis Bank for availing a term loan of Rs 1750 crore for the purpose of repayment of existing term loans from banks as a part of financial restructuring; and working capital facility of Rs 100 crore for the purpose of meeting working capital requirements of the company.

Maestros Electronics & Telecommunication System has received Purchase Order from DG Armed Forces Medical Service for Delivery of 338 pieces of Product named METSL TFT Display Cardiac Monitor with defibrillator. Broad consideration or size of the order is Rs 5.89 crore. The said order is expected to be executed by March 8, 2024.

Anant Raj has received approval for the issuance of equity shares or other convertible securities by way of Qualified Institutions Placement (QIP), for an aggregate consideration not exceeding Rs 500 crore only in accordance with the applicable laws including the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, each as amended, subject to receipt of all necessary approvals, if and to the extent required. The Board of Directors of the company at their meeting held on November 11, 2023 have inter-alia considered and approved the same. 

Biocon has reported results for second quarter ended September 30, 2023 (Q2FY24). The company has reported 96.49% fall in its net profit at Rs 34.70 crore for the quarter under review as compared to Rs 987.50 crore for the same quarter in the previous year. Total income of the company decreased marginally by 0.02% at Rs 588.30 crore for Q2FY24 as compared to Rs 588.40 crore for the corresponding quarter previous year. On consolidated basis, the company has reported over 2-fold jump in its net profit at Rs 172.70 crore for Q2FY24 as compared to Rs 81.80 crore for the same quarter in the previous year. Total income of the company increased by 51.84% at Rs 3,620.20 crore for Q2FY24 as compared to Rs 2,384.20 crore for the corresponding quarter previous year.